Investor Presentaiton
2
Safe Harbor Statement
Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the
future financial performance of IDEAYA Biosciences, Inc. (the "Company") and involve known and unknown risks, uncertainties and other factors that may cause the
actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any
forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,”
"plan," "anticipate," "intend," "believe," "estimate,” “predict,” “potential" or other comparable terminology. All statements other than statements of historical fact
could be deemed forward-looking, including the potentially addressable patient population for the Company's programs, any expectations regarding the Company's
target discovery platform or new target validation efforts as creating opportunities for research and development initiatives; any projections of financial information,
market opportunities, cash runway or profitability; any statements about historical results that may suggest trends for the Company's business; any statements of the
plans, strategies, and objectives of management for development programs or future operations; any statements about the timing of preclinical research, clinical
development, regulatory filings, manufacturing or release of data; any statements of expectation or belief regarding future events, potential markets or market size,
technology developments, or receipt of cash milestones, option exercise fees or royalties; and any statements of assumptions underlying any of the items mentioned.
The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these
expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and
uncertainties, many of which are beyond the Company's control. Such risks and uncertainties include, among others, the uncertainties inherent in the drug
development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory
approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and
defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. These and other important factors may cause
actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking
statements in this presentation are made only as of the date hereof. For a further description of the risks and uncertainties that could cause actual results to differ
from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the Company's periodic filings with
the Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K for the year ended December 31, 2022, and any current and periodic
reports filed thereafter. Except as required by law, the Company assumes no obligation and does not intend to update these forward-looking statements or to conform
these statements to actual results or to changes in the Company's expectations.
This presentation concerns anticipated products that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug
Administration (FDA). It is currently limited by Federal law to investigational use, and no representation is made as to its safety or effectiveness for the purposes for
which it is being investigated.
BIOSCIENCES
IDEAYAView entire presentation